Advances in hematopoietic cell transplantation have reduced the toxicity of both allogeneic and autologous transplantation. Decisions regarding the feasibility of transplantation should be individualized, and based upon physiological rather than chronological age. Bone Marrow Transplantation (2002) 29, 277-284. DOI: 10.1038/sj/bmt/1703382 Keywords: patient age; mortality; survival; GVHD; transplant; non-myeloablative Hematopoietic stem cell transplantation (HCT) for treatment of hematologic malignancies has traditionally been offered as curative therapy to children and young adults while, ironically, these diseases present more often in older patients. Decisions to place age limits on HCT have been driven by evidence of higher morbidity and mortality in older age groups based on regimen-related toxicity, higher risk of short-and long-term complications of therapy and higher incidence of co-morbidities which may increase transplant risk.
Hematopoietic stem cell transplantation (HCT) for treatment of hematologic malignancies has traditionally been offered as curative therapy to children and young adults while, ironically, these diseases present more often in older patients. Decisions to place age limits on HCT have been driven by evidence of higher morbidity and mortality in older age groups based on regimen-related toxicity, higher risk of short-and long-term complications of therapy and higher incidence of co-morbidities which may increase transplant risk.
Advances in hematopoietic cell transplantation have reduced mortality by reducing the period of neutropenia following transplantation, and by reducing the toxicity of conditioning regimens. In light of the above advances, physicians are now more likely to consider 'older' patients on an individual basis, and to consider physiological age, rather than chronological age in making decisions about suitability of individual patients as transplant candidates.
Disease features in the elderly
With a few notable exceptions, many hematologic malignancies increase in incidence with advancing age. The median age of diagnosis of AML is 65 years 1 -long considered to be prohibitively old for such interventions as BMT. The median age at diagnosis of multiple myeloma is 68 in men and 70 in women. While ALL incidence peaks at 10 years, a second smaller rise in incidence is seen in persons older than 70. The average age of presentation of myelodysplastic syndrome is approximately 70 years. 2 Correspondence: Dr LL Popplewell, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA NHL incidence increases steadily from childhood through the eighth decade of life. Aggressive lymphomas are more commonly seen in young adults, while indolent lymphomas seen more commonly in patients over 60 years of age.
Does advanced age translate a priori into poorer prognosis?
Intrinsic differences in the pattern of disease features mark older patients with a poorer outcome for diseases, such as AML and MDS. Cytogenetic status at diagnosis is an important prognostic indicator for outcome of AML treatment. Certain chromosomal abnormalities including inv16, t (15;17) , and t(8;21) predict a favorable outcome, while abnormalities of chromosome 5 and 7 confer a poorer prognosis. Favorable chromosomal abnormalities are less common, and unfavorable chromosome abnormalities are more common in older patient populations. 3, 4 Another example of a differential in prognostic signs at diagnosis is the Philadelphia chromosome in ALL, which occurs in only approximately 1% of children, but in over 30% of adults. 5 Leukemia in the elderly is also more likely to arise from a more primitive bone marrow stem cell. 6 AML arising from MDS and myeloproliferative disorders is likely to be intrinsically more resistant to chemotherapy due to the relatively high expression of genes which confer resistance. 7 Older patients are more likely to have a diagnosis of myelodysplastic syndrome prior to presentation with frank AML. Expressions of drug-resistance genes such as MDR-1 8, 9 are more commonly seen in the older patient. Microsatellite instability is also more commonly seen in patients who are older. 10 Advanced age is a strong and independent poor prognostic indicator in intermediate and high-grade NHL.
11 Both complete response (CR) rate and 5-year disease-free survival (DFS) are reduced in patients older than age 60 according to univariate analysis of statistically significant risk factors for poor prognosis in intermediate and highgrade non-Hodgkin's lymphoma (CR 62% vs 68% and 5-year DFS of 49% vs 67%). The age-adjusted international prognostic index defines the differences between the younger and older patient groups more specifically. While the distribution among the risk groups was similar for patients of both age groups, and the patients over 60 years of age had CR rates that were only slightly lower than those of the younger patients, the older patients with CRs had much lower rates of relapse-free survival, suggesting that more older patients died of lymphoma rather than of unre-lated causes. Older patients also had an observed death rate that was substantially higher than that of an age-matched cohort.
How does advanced age translate into a poorer outcome after HCT independent of prognostic features?
Independent of the above poor risk factors, older age may translate into a poorer outcome after HCT. Older patients are more likely to have concomitant medical problems, which may complicate the transplantation process. The likelihood of treatment-related mortality associated with induction chemotherapy in AML is approximately 5-10% in patients under the age of 60 years, compared with 25% in those over the age of 60. 12, 13 This comparison seems to support the concept that the prevalence of co-morbid diseases, such as diabetes mellitus, vascular insufficiency and renal impairment make the older patient less tolerant of the infections that inevitably occur in the setting of induction therapy-mediated immunosuppression and mucosal breakdown. Moreover, the metabolism of chemotherapeutic drugs may be delayed due to the age-related decline in excretory function, leading to exposure to higher drug levels and more toxicity. For example, the risk of cytarabineinduced cerebellar dysfunction is not related solely to age, but rather to the presence of renal and/or hepatic impairment. 14, 15 As will be discussed in depth in subsequent sections, complications of allogeneic transplantation such as acute and chronic graft-versus-host disease (GVHD) occur more often in older patients. Moreover, because many allogeneic grafts are donated by siblings, older patients receiving allogeneic transplants often have older donors. Grafts from older donors result in more acute GVHD than grafts from younger donors.
Autologous transplantation in older patients
Efforts at increasing availability of autologous HCT to older patients have focused on reducing the length of neutropenia following conditioning, and reduction in toxicity of the conditioning regimen. Studies from the IBMTR and ABMTR demonstrate a trend for increasing age of patients undergoing autologous HCT (see Figure 1 ). Kuznierz-Glaz and colleagues 16 found in a large retrospective study of 500 consecutive patients transplanted at Stanford University that, while disease status at the time of transplantation was the strongest predictive factor for event-free survival and relapse rate, age greater that 50 years was associated with a poorer outcome. Age was predictive for event-free survival, as well as for regimen-related mortality. However, the period of transplantation also influenced regimenrelated mortality, suggesting that improvements in transplantation over time may have influenced mortality. 16 The increased susceptibility to life-threatening infection following autologous HCT can be attributed to prolonged neutropenia following completion of the conditioning regimen. Consequently, measures aimed at reducing the period of neutropenia also reduce transplant-related mortality, particularly in older patients, who suffer higher mortality rates from infection. The use of mobilized peripheral blood progenitor cells in place of harvested bone marrow cells for autologous transplantation has improved the outcome of autologous transplantation in older patients. For example, a randomized trial comparing G-CSF-mobilized stem cells with autologous bone marrow for HCT was performed at six European centers following high-dose chemotherapy in 58 patients with advanced Hodgkin's disease or high-grade NHL. Patients received either G-CSF-mobilized stem cells or bone marrow for hemopoietic reconstitution. Time to neutrophil recovery above 0.5 × 10 9 /l was 11 days in the stem cell group vs 14 days in the autologous bone marrow group. Patients receiving stem cells also required fewer platelet transfusions, and became independent of transfusion of both platelets and red blood cells sooner, and required fewer days of hospitalization. 17 Apart from effects on hematopoiesis, direct toxicity of conditioning regimens increase transplant-related mortality of older patients. In 1994, the EBMT Lymphoma Working Party published a retrospective analysis of the outcome of autologous HCT for lymphoma patients aged 55 years or older. A matched analysis was conducted to reduce the potential bias introduced by patient selection. Of 901 patients, 82 were identified as over 55 years of age, while 23 of the 82 were over the age of 60 years. The median age for the older groups was 57 years and 5 months, compared with 37 years and 1 month in the younger group. All patients included received bone marrow as the source of stem cells. The actuarial PFS was 33% in the younger patients compared with 37% in the older group, while OS was 39% vs 38% for the two groups. For all toxic deaths, a higher rate was seen among the older patient group. This was primarily due to increased treatment-related toxicity in patients receiving TBI-based regimens, with no increase in toxicity in those having chemotherapy-only regimens. 18 For the older patient, choice of chemotherapy-only conditioning regimens as opposed to TBI-based conditioning regimens affects outcome in autologous HCT.
Focusing on autologous HCT for patients over the age of 50 years with first remission AML, the EBMT studied 111 results of transplantation in patients with a median age of 53 years. Approximately half of the patients received a radiation-based conditioning regimen while the remainder received a chemotherapy-based conditioning regimen. The results were compared with 786 autologous HCTs performed for AML in patients between the ages of 16 and 49 (median 35 years). The probability of leukemia-free sur-vival at 4 years was 34% in the older group vs 43% in the younger group, with a survival probability of 35% in the older group vs 48% in the younger group. Transplantrelated mortality was significantly higher in the older age group, without any associated increase in probability of relapse in the older age group. 19 While chemotherapy-based conditioning regimens result in less regimen-related toxicity in the older patient, radiation is an effective modality for treatment of hematologic malignancies. In an effort to re-incorporate radiation into a conditioning regimen without incurring the severe mucositis which so often complicates radiation-based conditioning, Press and colleagues 20 conducted a phase I/II trial using iodine 131 ( 131 I)-tositumomab (anti-CD20 antibody) in addition to etoposide and cyclophosphamide followed by ASCT in patients with relapsed B cell lymphomas. Fiftytwo patients (age range 34-58 years) received a trace-labeled infusion of 131 I-tositumomab followed by a therapeutic infusion of tositumomab labeled with an amount of 131 I calculated to deliver the target dose of radiation (20-27 Gy) to critical uninvolved organs. All patients were then given etoposide and cyclophosphamide followed by ASCT. The estimated overall survival (OS) and progression-free survival (PFS) of all treated patients compared favorably at 2 years with a nonrandomized control group of patients who had undergone transplantation, external-beam total-body irradiation, and etoposide and cyclophosphamide therapy. All patients had severe myelosuppression. Although mucositis, nausea and infections occurred in most patients treated with this regimen, these complications were usually mild to moderate in severity. 20 Although this protocol was not specifically directed towards the older patient, this new approach raises the possibility that the effective modality of radiation need not be eliminated from conditioning regimens for autologous transplantation in older patients.
Autologous HCT is the treatment of choice for symptomatic multiple myeloma patients who appear to be able to tolerate the toxicities associated with conditioning. 21 Vesole and colleagues have published results of autologous HCT for elderly patients. In multiple analyses, age has not been a statistically significant adverse prognostic feature for event-free survival (EFS) and overall survival (OS), 22 but rather this appears to be determined by cytogenetics, ␤ 2 -microglobulin, C-reactive protein and duration of prior therapy. 23, 24 A seminal study by this group examined patient outcome after autoHCT in relationship to age. Forty-nine patients aged over 65 years (median age 67, range 65 to 76 years) were evaluated, and compared with 49 younger pair mates matched for previously recognized prognostic factors. All patients received high-dose melphalan-based therapy. Seventy-six percent of the younger and 65% of the older group completed a second transplant. Comparing the two age groups, median durations of EFS and OS were 2.8/1.5 years for the older group and 4.8/3.3 years for the younger group. Age was not a significant predictor for either of these endpoints. 25 More recently, patients over the age of 70 were studied by the same group. Seventy newly diagnosed and refractory multiple myeloma patients (median age 72 years) were studied. Although the dose of melphalan was decreased to 140 mg/m 2 because of excessive mortality in the first 25 patients who received 
Impact of age on allogeneic HCT in older patients
Reviews by the IBMTR and ABMTR demonstrate increasing numbers of older patients receiving allogeneic HCT in recent years, just as they have increased participation in autologous HCT (see Figure 2) . To place our discussion in a historical context, we shall review some early data on allogeneic transplantation for patients of advanced age. In an early attempt to 'push the age barrier' in allogeneic transplantation, Blume and colleagues 27 from City of Hope reported results of allogeneic BMT in 86 patients with hematologic malignancies aged 30 to 54 years, following conditioning with high-dose radiochemotherapy. Disease-free survival was 44% for 37 patients in first remission of acute leukemia or in chronic phase CML, and 23% for 39 patients with leukemia beyond first complete remission (CR1) or with advanced stage CML, and 60% for patients with hematologic malignancies other than leukemia. The incidence of moderate to severe acute GVHD was 48% and of chronic GVHD, 26%. The major causes of failure were interstitial pneumonia and recurrent leukemia.
In 1986, Klingemann and colleagues 28 reported results of allogeneic transplants in patients 45 to 68 years of age. Again, the major causes of death were relapse of leukemia and idiopathic interstitial pneumonia. Patients over 50 years of age, many of whom were transplanted beyond CR1, did have the poorest survival rate. Among patients transplanted at an early stage of their disease, the actuarial survival rate was 22% at 3 years. The actuarial incidence of grade II to IV acute GVHD was 30% for allogeneic recipients 45 to 50 years of age, and did not differ significantly from the incidence observed in younger patients.
Efforts to explore the safety and effectiveness of transplantation in older populations continue. In a retrospective analysis, the European Group for Bone Marrow Transplantation (EBMT) reviewed data on 2195 allogeneic bone marrow transplant recipients treated for acute leukemia from 1979 to 1991. Patients transplanted between 1979 and 1987 ranged from 1 to 52 years in age (mean 25 years), while patients transplanted between 1987 and 1991 ranged from 1 to 56 years of age (mean 29 years). For AML, the 3-year transplant-related mortality (TRM) decreased from 39% to 26% after 1987, while the 5-year actuarial leukemia-free survival (LFS) increased from 45% to 57% after 1987. Similar improvements in outcome were seen in patients transplanted during the same period for ALL. Advanced age was identified as an independent poor prognostic factor in both ALL and AML. However, TRM improved significantly after 1986-1987 despite an older population of patients undergoing BMT (median age AML patients increased from 25 to 29, and median age of ALL patients increased from 21 to 23). Changes in transplant protocols during this period included use of cyclosporine in GVHD prophylaxis, decrease in use of total body irradiation, and a shorter interval from remission to BMT. 29 Prospective studies are under way to explore allogeneic transplantation in patients beyond the age of 60 years (see Table 1 ).
Conditioning regimens excluding total body irradiation have been explored not only for autologous, but also for allogeneic bone marrow transplantation. In 1994, Deeg and colleagues 30 reported results of a prospective randomized study comparing Cy/TBI vs Bu/Cy as conditioning regimens in patients with CML in chronic phase receiving marrow transplantation from HLA-identical siblings. There was no significant difference between the CY-TBI and the BU-CY groups in the 3-year probabilities of survival, relapse, event-free survival, speed of engraftment or incidence of veno-occlusive disease of the liver, while there was significantly more acute graft-versus-host disease in the CY-TBI group. Neutropenic fevers, positive blood cultures, hospitalizations and inpatient hospital days were significantly more common in the CY-TBI group than in the BU-CY group. Overall, the BU-CY regimen was better tolerated than Cy-TBI and was associated with survival and relapse probabilities similar to the CY-TBI regimen. 31 In hematopoietic stem cell transplantation, outcome at a fixed mg/kg dose is related to area under the plasma concentration-time curve (AUC) and average steady-state concentration (C SS ). Excessively high busulfan AUC or C SS is associated with an increase in hepatic veno-occlusive disease, while low levels are associated with a higher relapse rate in patients with chronic myelogenous leukemia (CML) 32 and with graft rejection. Optimal busulfan blood 2195 with acute Advanced age an independent poor risk leukemia, all ages factor, but TRM improves significantly over time despite increase in average age of transplant patients. CP = chronic phase; CR1 = first complete remission; TRM = treatment-related mortality.
levels have been defined. The availability of intravenous formulations has improved the ability to achieve optimal plasma levels for dose-targeting. Studies of combinations with other agents suggest that improvement in outcome, particularly in older patients, may continue to improve. A study of intravenous vs oral busulfan as part of a Bu/Cy conditioning regimen for allogeneic transplantation revealed fewer instances of VOD in patients receiving intravenous busulfan (20% vs 4.9%), and fewer VODrelated deaths (20% vs 3.3%). Day 100 mortality was also lower in the intravenous busulfan group (33% vs 13%). 33 Thus, the use of individual dose-adjustment may offset pharmacodynamic differences due to age.
As an example of good outcome in busulfan-based conditioning regimens in older patients, Deeg and colleagues 30 reviewed results of older patients (55 to 66 years of age) transplanted for MDS. Fifty patients between the ages of 55 and 66 years received allogeneic BMT. All 46 patients surviving more than 21 days engrafted. The cumulative incidence of relapse was 8% at 3 years. The Kaplan-Meier estimate of survival at 3 years was 59% (DFS 53%). Survival across all FAB categories was highest among patients enrolled in a protocol in which busulfan plasma levels were targeted to 600 to 900 ng/ml. Allogeneic marrow transplantation results with HCT in patients 55 to 66 years of age were encouraging, particularly for patients with favorablerisk cytogenetic features and patients who had been treated with a conditioning regimen based on plasma-leveltargeted busulfan.
Although results of non-radiation-based conditioning regimens are encouraging in older patients, radiation remains an effective tool for treatment of hematologic malignancies. Just as in autologous HCT, radioimmunotherapy has been explored in the allogeneic setting as a way to maintain the effectiveness of radiation without incurring radiation-associated regimen-related toxicity. The use of radiolabelled monoclonal antibodies has been explored in the setting of allogeneic transplantation. Preliminary results of a phase I/II study were reported by Matthews and colleagues 34 using targeted hematopoietic irradiation delivered by 131-I-labelled anti-CD45 antibody. Additional anti-leukemia therapy was administered with busulfan and cyclophosphamide. A favorable biodistribution was seen in all 15 patients at two dose levels. No grade III/IV toxicities were seen at the first dose level, whereas three cases of grade III mucositis and one grade IV toxicity with multiorgan failure were seen at the second dose level. The early results, with 14 of 15 patients surviving disease-free with a median follow-up of 8 months suggested that the delivery of targeted hematopoietic irradiation in addition to Bu/CY may improve outcome. This finding is of particular significance for older candidates for transplantation, as it incorporates an effective anti-leukemia therapy (radiation) into the conditioning regimen without incurring the toxicity which affects older patients so profoundly.
Just as the use of peripheral blood progenitor cells in HCT has reduced the length of neutropenia and improved outcomes for older patients, use of allogeneic stem cells in place of harvested bone marrow has reduced hospital stays for patients receiving allogeneic HCT. Pilot studies using allogeneic peripheral blood stem cells (PBSC) for matched sibling transplantation were first published in 1995. Several phase II studies followed, all demonstrating more rapid engraftment than that historically expected from allogeneic bone marrow transplantation. In a collaborative effort by the Fred Hutchinson Cancer Research Center, Stanford University, and the City of Hope, the first randomized phase III trial directly comparing allogeneic PBSC vs bone marrow was performed. One hundred and seventy-two patients received either bone marrow or G-CSF-mobilized peripheral blood cells from HLA-identical relatives after conditioning. The recovery of both neutrophils and platelets was faster with peripheral blood cells than with marrow (time to engraftment for neutrophils 16 days for peripheral blood cells vs 21 days for bone marrow, time of engraftment for platelets 13 days vs 19 days). The cumulative incidence of grade II-IV aGVHD at 100 days was similar in the two groups. The cumulative incidence of cGVHD was 46% vs 35% with marrow. The estimated overall probability of survival at 2 years was 66% with PBSC vs 54% with marrow. Disease-free survival at 2 years was 65% with PBSC vs 45% with marrow. 35 Thus, in most instances, the use of allogeneic PBSC provides more rapid engraftment and, in many studies, reduced mortality during the early post-transplant period, a significant advantage for older patients who may tolerate complications of delayed engraftment poorly.
GVHD incidence in the older patient

Acute GVHD
The incidence of acute GVHD (aGVHD) is reported to be higher in older patients, although this observation is not a consistent finding in clinical trials. Both donor and recipient age have been reported to influence aGVHD incidence. The International Bone Marrow Transplantation Registry (IBMTR) has reported data from 2036 recipients of HLAidentical sibling transplant for leukemia or aplastic anemia to identify risk factors for aGVHD. Older patients were at increased risk for aGVHD. However, the age gradient was modest. When female to male transplants were excluded, age was not a significant risk factor. 36 In a study of 192 patients with ALL transplanted from HLA-identical sibling Bone Marrow Transplantation donors following a consistent conditioning regimen and identical GVHD prophylaxis, Doney and colleagues 37 reported an increased risk of aGVHD was associated with increasing donor age. Increasing patient age was associated with a decreased probability of both survival and relapsefree survival (RFS). Increasing donor age was associated with an increased probability of developing grades II-IV aGVHD and a decreased probability of survival.
Weisdorf et al 38 analyzed risk factors associated with aGVHD following allogeneic bone marrow transplantation in 469 patients with histocompatible sibling donors transplanted between 1979 and 1987. On univariate analysis, patient or donor age above 18 years was significantly associated with increased GVHD risk (63% vs 27%). However, no additional incremental risk was noted in older adults.
Nash and colleagues 39 reported the incidence of aGVHD in 446 patients receiving transplant of marrow from HLAidentical siblings and a combination of cyclosporine and methotrexate for GVHD prophylaxis. Patients over the age of 40 years were more likely to develop grades III-IV GVHD among all patients who developed and grade II-IV aGVHD. Another study, however, by Hägglund and colleagues 40 involved 291 consecutive BMT from HLA-identical siblings, and age did not appear to correlate with aGVHD on multivariate analysis. In conclusion, the data would suggest that, if an age gradient for aGVHD does exist, it is modest at best, and occurs in a patient population which may be physically less able to tolerate its outcome.
Chronic GVHD
Several independent studies have documented an increase in cGVHD in patients who have developed aGVHD. If aGVHD is increased by advancing age in a transplant recipient, then age may also contribute to cGVHD by the same mechanism. Age has been identified as a significant independent risk factor for cGVHD in older patients. A study of 2534 recipients of HLA-identical sibling transplants surviving at least 90 days post transplantation was conducted by the IBMTR in 1990. The strongest risk factor for cGVHD was a history of aGVHD. When patients with a history of grade II-IV aGVHD were excluded from study, age above 20 years emerged as an independent risk factor on multivariate analysis, with RR of 2.03 in patients with no prior history of aGVHD, and 1.58 in patients with a history of grade I GVHD. 41 Similar findings emerged in a study by Ochs et al 42 in a review of 469 patients transplanted with matched sibling allogeneic bone marrow. Recipient age above 18 years increased the risk for cGVHD with a RR of 1.67. However, there was no incremental risk with increasing age. A retrospective analysis of 551 consecutive recipients in a single center by Carlens et al 43 revealed that high recipient age was the single most important risk factor for cGVHD. A multivariate analysis in recipients of bone marrow from unrelated donors showed recipient age alone to be significantly associated with cGVHD. A study by Aschan et al 44 of 182 leukemia patients after allogeneic bone marrow transplantation revealed that aGVHD rates were similar in patients over 30 years old vs under 30 years. However, older patients benefited more significantly from double GVHD prophylaxis with CsA/MTX or from receiving T cell-depleted (TCD) transplants -the benefit being reflected in a lower incidence of cGVHD, and increased survival rates. Older patients receiving CsA/MTX prophylaxis or TCD transplants did not have worse survival rates than younger patients. 44 In summary, cGVHD rates do appear to increase in alloBMT performed beyond age 18, but no significant incremental risk with advancing age appears to exist. The most effective method for decreasing incidence of cGVHD in older patients appears to be successful prophylaxis for aGVHD.
T cell-depleted allogeneic transplantation
One potential avenue for reducing the toxicity of allogeneic transplantation is by depletion of the T-lymphocytes of the allogeneic graft. Substantial reduction of GVHD and its complications could potentially reduce morbidity and mortality of allogeneic transplantation in older patients. Papadopoulos and colleagues 45 at Memorial Sloan-Kettering Cancer Center have transplanted patients with AML in first and second complete remission with T cell-depleted allogeneic bone marrow from HLA-identical siblings following myeloablative conditioning with FTBI, thiotepa and cyclophosphamide. Patients were 16 to 51 years of age with a median of 36.7 years. Anti-thymocyte globulin and methylprednisolone were used in the early peri-transplant period for patients at risk for immune-mediated graft rejection. Relapse rates were low and there were no cases of grade II to IV aGVHD. For patients transplanted for AML in first complete remission, the probability of DFS at 4 years of age was 77.4% with a median follow-up of 56 months. Regimen-related toxicity at 100 days for patients transplanted in first complete remission was 9.7%, while the cause-specific probability of death by all causes other than leukemic relapse was 19.4%. There were no cases of immune-mediated graft rejection and no cases of grade II to IV acute graft-versus-host disease (GVHD). All survivors enjoy Karnofsky performance scores (KPS) of 100%, except two patients with KPS of 80% to 90%. 45 T cell depletion does seem to increase the infectious complications of allogeneic transplantation, as well as the incidence of secondary lymphomas and may also affect relapse rates. Infusion of aliquots of donor-derived T cells following transplantation has been explored as a means of reintroduction of these cells in an attempt to reconstitute the immune system of the patient without producing severe GVHD. 46 
Non-myeloablative allogeneic transplantation
Evidence for a graft-versus-tumor (GVT) effect is supported by observations such as decreased relapse rates in allogeneic vs syngeneic transplants, 47 fewer relapses in allogeneic transplants vs autologous transplants, 48, 49 and in patients with mild to moderate aGVHD vs no aGVHD, 50 and by the effectiveness of donor lymphocytes (DLI) for treatment of disease which has recurred after allogeneic transplantation. Non-myeloablative transplant approaches achieve allogeneic engraftment without marrow ablation. They may be successful in settings where a graft-versustumor (GVT) effect is sufficiently potent to eradicate the underlying malignancy. Many initial reports of non-myeloablative allogeneic HCT included patients who were ineligible for conventional BMT because of older age or organ dysfunction. As a result, reports of DFS, TRM, etc, in non-myeloablative protocols often include older patients, and in fact, the mean age of patient in the non-myeloablative protocols is often in the mid-50s.
Several trials have been performed using allogeneic G-CSF mobilized blood stem cells following a non-myeloablative conditioning regimen. [51] [52] [53] Results suggested that this approach might be particularly attractive in an older patient population.
Testing the feasibility of this approach on an older patient population (median age 56 years, range 31-72 years), McSweeney and colleagues 53 transplanted 45 patients with myeloid leukemias and B cell malignancies who were ineligible for conventional allografting because of age, preceding high-dose therapy, or organ dysfunction. Immunosuppression involved TBI, 200 cGy, before and cyclosporine and mycophenolate mofetil after hematopoietic cell transplant from HLA-identical sibling donors. DLI was administered on or beyond day ϩ65 only to patients with mixed T cell chimerism or disease progression and no evidence of GVHD. Of the 36 patients who achieved sustained engraftment beyond day ϩ28, 53% achieved complete remission. Grades II or III acute GVHD occurred in 46% of patients with sustained engraftment, and no grade IV GVHD was seen. Chronic GVHD occurred in 69% of evaluable patients, with 63% requiring systemic immunosuppressive therapy. Regimen-related toxicities and myelosuppression were mild, allowing 17 of 32 eligible patients to have outpatient transplants, while the remainder were hospitalized for a median of 8 days. With a median followup of 429 days, survival was 66.7%, nonrelapse mortality 6.7% and relapse mortality was 26.7%. Hence, non-myeloablative conditioning regimens preceding infusion of allogeneic stem cells seem to be well tolerated, with acceptable rates of GVHD, even in older patients, and are being explored in a wide range of hematologic malignancies, including multiple myeloma, lymphoma and AML, all of which are more common in older patients.
Conclusion
Advanced patient age at the time of transplant is associated with increased transplant-related morbidity and mortality. Changes in transplantation practices, including use of cytokines, peripheral blood stem cells rather than harvested bone marrow, less toxic conditioning regimens, and development of methods for delivering more targeted therapy, have helped to reduce the toxicity of both autologous and allogeneic conditioning regimens for older patients. In some cases, this allows effective myeloablation prior to hematopoietic stem cell infusion without increased toxicity. In other cases, an altogether different tactic has been used, allowing donor engraftment without complete myeloablation and its accompanying toxicities. More effective GVHD prophylaxis has reduced the aGVHD-related morbidity and mortality and also reduced the secondary appear-ance of cGVHD. These changes in transplantation have allowed patients of more advanced age to be considered on an individual basis for transplantation. In the absence of severely compromised organ function or other accompanying illness, age alone should not be considered a contraindication to transplantation. There should be no upper age limit for hematopoietic stem cell transplantation.
